Skip to main content
NOVAVAX INC logo

NOVAVAX INC — Investor Relations & Filings

Ticker · NVAX ISIN · US6700024010 LEI · 529900J4GJHPEPQ23205 US Manufacturing
Open in API
Filings indexed 1,095 across all filing types
Latest filing 2019-08-07 Interim / Quarterly Rep…
Country US United States of America
Listing US NVAX

About NOVAVAX INC

https://www.novavax.com/?locale=US

Novavax Inc. is a biotechnology company that develops and commercializes vaccines to prevent serious infectious diseases. The company utilizes a proprietary, protein-based vaccine technology platform, which includes its novel Matrix-M™ adjuvant, to create its vaccine candidates. Its primary commercial product is a protein-based COVID-19 vaccine, Nuvaxovid™. Novavax's research and development pipeline is focused on addressing significant health needs, including influenza and a combination COVID-19-influenza vaccine. The company's strategy emphasizes advancing its pipeline assets and establishing strategic partnerships to maximize the global health impact of its technology.

Recent filings

Filing Released Lang Actions
FORM 10-Q
Interim / Quarterly Report Q2 2019
2019-08-07 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text describes the consummation of an asset purchase agreement transaction between Novavax, Inc. and Paragon Bioservices, including a joint press release. There are no detailed financial statements or comprehensive financial analysis included, only a description of the transaction and a reference to an exhibit (the press release). The document is about a specific event related to a transaction, not a full annual or quarterly report, audit, or earnings release. Therefore, the most appropriate classification is a Capital/Financing Update (CAP), as it relates to a significant transaction affecting the company's assets and capital structure.
2019-08-01 English
FORM 8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated June 28, 2019, by Novavax, Inc. The key content is the submission of matters to a vote of security holders at the Annual Meeting held on June 28, 2019. It details the voting results for several proposals including election of directors, advisory approval of executive compensation, approval of stock incentive plans, and ratification of the independent auditor. This matches the description of a Declaration of Voting Results & Voting Rights Announcements, which reports official results from shareholder votes at a general meeting. The document is about 6315 characters, contains detailed voting results, and is not merely an announcement of a report or a certification. Therefore, the correct classification is DVA (Declaration of Voting Results & Voting Rights Announcements). Confidence is high given the clear match to the category.
2019-07-02 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text describes the entry into a material definitive agreement involving the sale of assets and related agreements. It also includes a Regulation FD disclosure and a joint press release as an exhibit. There are no financial statements or detailed financial data presented, only a description of the transaction and related agreements. This type of filing is typically categorized as a Regulatory Filing (RNS) because it is a current report disclosing material events but not a full financial report or other specific report type. The document length is 7,902 characters, which is consistent with a detailed 8-K filing but not a full annual or quarterly report. Therefore, the appropriate classification is Regulatory Filings (RNS).
2019-07-01 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A proxy statement filed with the SEC, specifically titled as a Definitive Proxy Statement and Definitive Additional Materials. It relates to the Annual Meeting of Stockholders, including voting items such as election of directors, advisory votes on executive compensation, amendments to stock plans, and ratification of the auditor. The content is focused on proxy solicitation and providing information to shareholders to vote at the meeting. It does not contain financial statements or detailed financial analysis, nor is it an announcement of a report publication. Therefore, the document fits the category of Proxy Solicitation & Information Statement (PSI). The document length (6197 characters) and detailed proxy content support this classification with high confidence.
2019-05-16 English
DEF 14A
Proxy Solicitation & Information Statement
2019-05-16 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.